# NEXT SESSION — BD Platform

**Written:** 2026-05-24 (Session 29)  
**Last commits:** `84d58dbc` (company_intake.py), `964fe833` (v28 migration), `0791228c` (seed_targets.py)  
**Last data change:** 13 ownership_edges backfilled with deal_id; 173 drug_targets rows; 137 entity_edges TARGETS; 600 COMPETES_WITH edges

---

## Session 29 Summary — Relationship Completeness Sprint (All 3 Phases Done)

### What was built

**Phase 1 — COMPETES_WITH edges**
- `entity_edges` table (migration v26) — universal predicate graph layer
- 600 bidirectional COMPETES_WITH edges, 5 areas, deterministic (no LLM)
- 172 validation tests of type `competes_with_edge_exists`

**Phase 2 — Normalized target nodes**
- `drug_targets` junction table fully built and populated
- 39 canonical targets (including bispecifics + trispecifics)
- 84.2% area-linked drug coverage (80/95 drugs have ≥1 drug_targets row)
- 137 entity_edges TARGETS rows for graph queries
- Validation test `phase2_target_node_coverage` (id=1076)

**Phase 3 — deal_id FK**
- `ownership_edges.deal_id` FK column added (migration v28)
- 13 edges backfilled across 3 acquisitions (UCB/Candid, UCB/Antengene, Merck/Prometheus)
- `write_acquisition_edges()` + `write_license_edges()` added to company_intake.py

### Validation suite
- **1000 tests total** (up from 828)
- **979 pass / 16 fail / 5 skip**
- Failures: all pre-existing (company_area_check ×12, overlap_check ×3, confidence_requires_source ×1)

---

## Outstanding — Pre-Existing Failures (not introduced this sprint)

### P1 Blockers (fix before next feature work)

**1. overlap_check failures (3):**
```
cizutamig-tcell-overlap     expected=Direct    got=Watch
itepekimab-tslp-overlap     expected=Direct    got=Watch
rozanolixizumab-fcrn-overlap expected=Direct   got=Watch
```
These drugs have `overlap='Watch'` in `drug_area_scores` but the validation test expects `Direct`. Either the test expectation is wrong or the enrichment run set an incorrect value. Check `drug_area_scores` and update the lower value.

**2. confidence_requires_source (1):**
```
tralokinumab × il4ra — confidence=confirmed, source_url=null
```
Pre-existing E6 violation flagged in the previous session. Fix: PATCH `drug_area_scores` row to set source_url or downgrade confidence_level to 'supported'.

**3. company_area_check (12):**
Pre-existing enrichment coverage gaps. Low urgency — these flag missing `company_areas` rows for companies with relevant pipelines. Can be addressed in bulk during next enrichment run.

---

## Next Steps (in priority order)

### P0 — Fix the 3 overlap test failures
Quick fix: check drug_area_scores for cizutamig/tcell, itepekimab/tslp, rozanolixizumab/fcrn and either patch the data or correct the test.

### P1 — Fix tralokinumab E6 violation
```python
PATCH drug_area_scores WHERE drug_id='tralokinumab' AND area_id='atopy'
  SET source_url='https://www.leo-pharma.com/tralokinumab'
  -- or downgrade confidence_level to 'supported'
```

### P2 — Phase 2 coverage gap (15.8% unmapped)
19 area-linked drugs still have no target node. The easy wins remaining:
- Drugs with `+` notation (SPY120: α4β7 + TL1A, SPY130: α4β7 + IL-23) — map to `tl1a_a4b7` and new `a4b7_il23p19` targets
- `guselkumab + golimumab` combo study — map each component drug separately
- `Lutikizumab: IL-1α/β` — add new target `il1ab` with class=cytokine
- `Iscalimab: CD40` — add `cd40` target
- `Omalizumab: IgE` — add `ige` target

### P3 — What Meridian can now answer (new capabilities)
The graph now supports:
1. "Which drugs compete with [drug X] in [area Y]?" — via entity_edges WHERE subject_id=X AND predicate='COMPETES_WITH' AND scope_area_id=Y
2. "What does [drug X] target?" — via entity_edges WHERE subject_id=X AND predicate='TARGETS'
3. "Which drugs target TL1A?" — via entity_edges WHERE object_id='tl1a' AND predicate='TARGETS'
4. "Which UCB drugs came from the Candid acquisition?" — via ownership_edges WHERE deal_id=19

### P4 — Meridian maturity: advance to L3
The remaining bottleneck from the maturity assessment was relationship completeness. With Phases 1–3 done:
- COMPETES_WITH ✅
- drug → TARGETS → target ✅
- ownership_edges.deal_id ✅
- Still missing: company → ACTIVE_IN → area edges (currently inferred at runtime from company_areas table)

Next maturity milestone: area-level company graph (ACTIVE_IN edges so "who is active in IBD?" is a single graph query, not a join).

---

## Active Uncertain Cases (for future manual review)

### COMPETES_WITH — uncertain bispecifics not yet seeded
| Drug | Target text | Issue |
|------|-------------|-------|
| SPY230 | IL-23 + TL1A | `+` notation — maps to tl1a_il23p19 if confirmed bispecific |
| APG279 | IL-13 + OX40L | `+` notation — maps to new il13_ox40l bispecific |
| SPY130 | α4β7 + IL-23 | `+` notation — maps to new a4b7_il23p19 |
| SPY120 | α4β7 + TL1A | `+` notation — maps to tl1a_a4b7 (already exists) |

Resolve by confirming bispecific format in press releases, then add to TARGET_TEXT_TO_ID and BISPECIFIC_COMPONENTS in both seed scripts.

### drug_targets — niche targets outside BD scope (no action needed)
RIPK1, BAFF-R, IgE, CLDN18.2, C5, C2, C1q, CD40, CD38, HIF-2α, FGFR2b, IGF-1R, GLP-1R, Calcineurin — drugs with these targets are in the DB for completeness but are non-core to current BD areas.

---

## Key DB State (end of Session 29)
| Table | Rows |
|-------|------|
| entity_edges (COMPETES_WITH) | 600 |
| entity_edges (TARGETS) | 137 |
| drug_targets | 173 |
| targets | 39 |
| ownership_edges (with deal_id) | 13 |
| validation_tests | 1000 |
| validation suite pass rate | 97.9% |
